Civitas considers options as inhaled levodopa curtails dyskinesia

Civitas Therapeutics is mulling its Phase III clinical trial design and financing options based on the success of a Phase IIb trial that showed the company's inhaled levodopa, CVT-301, provided rapid onset and relief from dyskinesia in patients with Parkinson's disease.

Civitas Therapeutics is mulling its Phase III clinical trial design and financing options based on the success of a Phase IIb trial that showed the company's inhaled levodopa, CVT-301, provided rapid onset and relief from dyskinesia in patients with Parkinson's disease.

Chelsea, Massachusetts-based Civitas is developing CVT-301 to help Parkinson's patients curtail dyskinesia, or involuntary loss of motor function, that happens...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category